Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Equities researchers at Cantor Fitzgerald boosted their FY2017 earnings per share estimates for Aerie Pharmaceuticals in a research report issued on Thursday. Cantor Fitzgerald analyst E. Piros now forecasts that the company will earn ($2.99) per share for the year, up from their prior estimate of ($3.15). Cantor Fitzgerald has a “Overweight” rating and a $62.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aerie Pharmaceuticals’ FY2018 earnings at ($2.10) EPS.
Several other research firms have also commented on AERI. Aegis increased their target price on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. HC Wainwright reissued a “buy” rating and set a $69.00 target price on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. Needham & Company LLC increased their target price on shares of Aerie Pharmaceuticals from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, May 25th. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, May 22nd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a research note on Tuesday, April 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $65.69.
COPYRIGHT VIOLATION NOTICE: “FY2017 EPS Estimates for Aerie Pharmaceuticals, Inc. (AERI) Raised by Analyst” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/fy2017-eps-estimates-for-aerie-pharmaceuticals-inc-aeri-raised-by-analyst-updated-updated.html.
Shares of Aerie Pharmaceuticals (AERI) traded down 2.08% on Monday, hitting $56.40. 197,546 shares of the stock were exchanged. The company’s market cap is $1.90 billion. Aerie Pharmaceuticals has a one year low of $16.61 and a one year high of $59.50. The firm’s 50-day moving average is $53.99 and its 200-day moving average is $46.83.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.02.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after buying an additional 2,598,596 shares in the last quarter. Vanguard Group Inc. raised its stake in Aerie Pharmaceuticals by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,392,525 shares of the company’s stock worth $63,151,000 after buying an additional 92,463 shares in the last quarter. State Street Corp raised its stake in Aerie Pharmaceuticals by 36.9% in the fourth quarter. State Street Corp now owns 820,644 shares of the company’s stock worth $31,059,000 after buying an additional 221,146 shares in the last quarter. FMR LLC raised its stake in Aerie Pharmaceuticals by 178.7% in the first quarter. FMR LLC now owns 320,500 shares of the company’s stock worth $14,535,000 after buying an additional 205,500 shares in the last quarter. Finally, Columbus Circle Investors raised its stake in Aerie Pharmaceuticals by 20.8% in the first quarter. Columbus Circle Investors now owns 282,309 shares of the company’s stock worth $12,803,000 after buying an additional 48,689 shares in the last quarter. Institutional investors and hedge funds own 92.01% of the company’s stock.
In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $55.95, for a total transaction of $1,119,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 9.36% of the stock is owned by insiders.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.